• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

围绝经期和绝经后女性激素、代谢标志物与骨量之间的关联。

Associations between hormones, metabolic markers, and bone mass in perimenopausal and postmenopausal women.

作者信息

Lu Bingru, Han Qunxiao, Zhao Shiyu, Ding Shan, Bao Guolin, Liu Yiqing

机构信息

Department of Clinical Laboratory, Shandong Provincial Hospital Affiliated to Shandong First Medical University, 324 Jingwuweiqi Rd, Huaiyin, Jinan, 250021, Shandong, People's Republic of China.

Department of Clinical Laboratory, Binzhou Central Hospital, Binzhou, 251700, Shandong Province, China.

出版信息

J Bone Miner Metab. 2025 Mar 5. doi: 10.1007/s00774-025-01595-x.

DOI:10.1007/s00774-025-01595-x
PMID:40044973
Abstract

INTRODUCTION

To explore the associations between hormones, metabolic markers, and low bone mass in perimenopausal and postmenopausal women.

MATERIALS AND METHODS

A total of 198 women were enrolled in this study. The correlations between hormones, metabolic markers, and BMD were analyzed. Risk factors for bone loss were identified. Receiver operating characteristic (ROC) curves were used to display the predictive power of these risk factors.

RESULTS

The years since menopause and the levels of glucose (GLU), follicle-stimulating hormone (FSH), and luteinizing hormone (LH) were inversely correlated with BMD, while estrogen and testosterone were positively correlated with BMD. Age (odds ratio [OR] 1.232; 95% confidence interval [CI] 1.106-1.372; p < 0.001), GLU (OR 1.848; 95% CI 1.116-3.059; p = 0.017), and FSH (OR 1.089; 95% CI 1.003-1.182; p = 0.042) were identified as risk factors for bone loss. Age (AUC = 0.884, 95% CI 0.833-0.935), FSH (AUC = 0.824, 95% CI 0.760-0.888), and GLU (AUC = 0.683, 95% CI 0.599-0.768) demonstrated significant discrimination capability for bone loss. The combined application of these factors resulted in a better prediction effect (AUC = 0.930, 95% CI 0.893-0.967).

CONCLUSIONS

Age, FSH, and GLU were found to be specific risk factors for bone loss. The utilization of these factors offers compelling predictive power for bone loss in perimenopausal and postmenopausal women.

摘要

引言

探讨围绝经期和绝经后女性激素、代谢标志物与低骨量之间的关联。

材料与方法

本研究共纳入198名女性。分析了激素、代谢标志物与骨密度之间的相关性。确定了骨质流失的危险因素。采用受试者工作特征(ROC)曲线来展示这些危险因素的预测能力。

结果

绝经年限以及血糖(GLU)、促卵泡激素(FSH)和促黄体生成素(LH)水平与骨密度呈负相关,而雌激素和睾酮与骨密度呈正相关。年龄(比值比[OR]1.232;95%置信区间[CI]1.106 - 1.372;p < 0.001)、GLU(OR 1.848;95% CI 1.116 - 3.059;p = 0.017)和FSH(OR 1.089;95% CI 1.003 - 1.182;p = 0.042)被确定为骨质流失的危险因素。年龄(曲线下面积[AUC]=0.884,95% CI 0.833 - 0.935)、FSH(AUC = 0.824,95% CI 0.760 - 0.888)和GLU(AUC = 0.683,95% CI 0.599 - 0.768)对骨质流失具有显著的判别能力。这些因素的联合应用产生了更好的预测效果(AUC = 0.930,95% CI 0.893 - 0.967)。

结论

年龄、FSH和GLU被发现是骨质流失的特定危险因素。利用这些因素可为围绝经期和绝经后女性的骨质流失提供有力的预测能力。

相似文献

1
Associations between hormones, metabolic markers, and bone mass in perimenopausal and postmenopausal women.围绝经期和绝经后女性激素、代谢标志物与骨量之间的关联。
J Bone Miner Metab. 2025 Mar 5. doi: 10.1007/s00774-025-01595-x.
2
Follicle-stimulating hormone is associated with low bone mass in postmenopausal women.卵泡刺激素与绝经后妇女的低骨量有关。
Osteoporos Int. 2023 Apr;34(4):693-701. doi: 10.1007/s00198-023-06676-z. Epub 2023 Jan 24.
3
Long-term hormone therapy for perimenopausal and postmenopausal women.围绝经期和绝经后女性的长期激素治疗
Cochrane Database Syst Rev. 2017 Jan 17;1(1):CD004143. doi: 10.1002/14651858.CD004143.pub5.
4
Dehydroepiandrosterone for women in the peri- or postmenopausal phase.绝经前后阶段女性使用脱氢表雄酮。
Cochrane Database Syst Rev. 2015 Jan 22;1(1):CD011066. doi: 10.1002/14651858.CD011066.pub2.
5
Long term hormone therapy for perimenopausal and postmenopausal women.围绝经期和绝经后女性的长期激素治疗。
Cochrane Database Syst Rev. 2012 Jul 11(7):CD004143. doi: 10.1002/14651858.CD004143.pub4.
6
Hormone therapy for sexual function in perimenopausal and postmenopausal women.围绝经期和绝经后女性性功能的激素治疗
Cochrane Database Syst Rev. 2013 Jun 5(6):CD009672. doi: 10.1002/14651858.CD009672.pub2.
7
Evaluation of the therapeutic effect of estrogen replacement therapy combined with autologous serum therapy in controlling severe dry eye disease in perimenopausal women.雌激素替代疗法联合自体血清疗法对围绝经期女性重度干眼症的治疗效果评估
Sci Rep. 2025 Jul 18;15(1):26096. doi: 10.1038/s41598-025-03638-9.
8
Testosterone for peri- and postmenopausal women.绝经前后女性的睾酮治疗
Cochrane Database Syst Rev. 2005 Oct 19(4):CD004509. doi: 10.1002/14651858.CD004509.pub2.
9
Recombinant luteinizing hormone (rLH) and recombinant follicle stimulating hormone (rFSH) for ovarian stimulation in IVF/ICSI cycles.重组促黄体生成素(rLH)和重组促卵泡生成素(rFSH)用于体外受精/卵胞浆内单精子注射周期中的卵巢刺激。
Cochrane Database Syst Rev. 2017 May 24;5(5):CD005070. doi: 10.1002/14651858.CD005070.pub3.
10
[Association between obesity and the risk of microvascular complications in Yinzhou District, Ningbo adults with type 2 diabetes mellitus].[宁波鄞州区2型糖尿病成年患者肥胖与微血管并发症风险的相关性]
Wei Sheng Yan Jiu. 2025 Jul;54(4):608-620. doi: 10.19813/j.cnki.weishengyanjiu.2025.04.012.

引用本文的文献

1
Association between immune-inflammatory index and osteoporosis: a systematic review and meta-analysis.免疫炎症指标与骨质疏松症之间的关联:一项系统评价和荟萃分析。
Eur J Med Res. 2025 Jul 16;30(1):632. doi: 10.1186/s40001-025-02893-w.
2
Comment on "Associations between hormones, metabolic markers, and bone mass in perimenopausal and postmenopausal women".关于“围绝经期和绝经后女性激素、代谢指标与骨量之间的关联”的评论
J Bone Miner Metab. 2025 May 3. doi: 10.1007/s00774-025-01605-y.

本文引用的文献

1
Bone Loss in Diabetes Mellitus: Diaporosis.糖尿病性骨丢失:骨质疏松症。
Int J Mol Sci. 2024 Jul 2;25(13):7269. doi: 10.3390/ijms25137269.
2
Postmenopausal Osteoporosis.绝经后骨质疏松症
N Engl J Med. 2023 Nov 23;389(21):1979-1991. doi: 10.1056/NEJMcp2307353.
3
FSH-blocking therapeutic for osteoporosis.用于骨质疏松症的 FSH 阻断治疗。
Elife. 2022 Sep 20;11:e78022. doi: 10.7554/eLife.78022.
4
Association between lipid biomarkers and osteoporosis: a cross-sectional study.脂类生物标志物与骨质疏松症的相关性:一项横断面研究。
BMC Musculoskelet Disord. 2021 Sep 6;22(1):759. doi: 10.1186/s12891-021-04643-5.
5
Critical review of bone health, fracture risk and management of bone fragility in diabetes mellitus.糖尿病患者骨健康、骨折风险及骨脆性管理的批判性综述
World J Diabetes. 2021 Jun 15;12(6):706-729. doi: 10.4239/wjd.v12.i6.706.
6
Postmenopausal Osteoporosis: Latest Guidelines.绝经后骨质疏松症:最新指南
Endocrinol Metab Clin North Am. 2021 Jun;50(2):167-178. doi: 10.1016/j.ecl.2021.03.009.
7
Fasting glucose level and the risk of incident osteoporosis in the Koreans.空腹血糖水平与韩国人骨质疏松症发病风险的关系。
Bone. 2021 Jan;142:115690. doi: 10.1016/j.bone.2020.115690. Epub 2020 Oct 21.
8
Osteoporosis: Pathophysiology and therapeutic options.骨质疏松症:病理生理学与治疗选择。
EXCLI J. 2020 Jul 20;19:1017-1037. doi: 10.17179/excli2020-2591. eCollection 2020.
9
The Interplay Between Bone and Glucose Metabolism.骨与糖代谢的相互作用。
Front Endocrinol (Lausanne). 2020 Mar 24;11:122. doi: 10.3389/fendo.2020.00122. eCollection 2020.
10
Positive and negative regulators of osteoclast apoptosis.破骨细胞凋亡的正负调节因子。
Bone Rep. 2019 Oct 21;11:100225. doi: 10.1016/j.bonr.2019.100225. eCollection 2019 Dec.